As the oncogenic activity of nuclear FGFR1, which so far has been reported to be kinase-independent, cannot be targeted with TKI or with FGFR1-specific antibodies/antibody-based therapeutics, expanding our knowledge of the function of nuclear FGFR1 and the mechanism of its nuclear trafficking may facilitate the development of novel cancer treatment strategies that inhibit the pool of previously untargeted nuclear FGFR1. Here, FGFR1 is linked to cancer.